Nishadil
Nishadil Ads Nishadil Astrology Nishadil Developers Nishadil Domains Nishadil Drive Nishadil Finance Nishadil Pay Nishadil Weather Nishdil Calendar Rewards
Signup Signin
Washington | 20°C (overcast clouds)
Topic Feed

Cytk

Showing the latest stories and updates for this topic.
Navigating the Nuances of Cytokinetics: December's Catalyst and the Investment Conundrum

Navigating the Nuances of Cytokinetics: December's Catalyst and the Investment Conundrum
The Unraveling of a Biotech Dream: When Investor Optimism Meets Harsh Reality

The Unraveling of a Biotech Dream: When Investor Optimism Meets Harsh Reality
The Echo of Disappointment: When Promises Fade for Cytokinetics Investors

The Echo of Disappointment: When Promises Fade for Cytokinetics Investors
The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?
Carisma Therapeutics Shares Soar Over 130% on Groundbreaking Moderna Collaboration for In Vivo CAR-M Therapies

Carisma Therapeutics Shares Soar Over 130% on Groundbreaking Moderna Collaboration for In Vivo CAR-M Therapies
Breakthrough Hope for HCM Patients: Cytokinetics Unveils Promising Aficamten Data at European Cardiology Congress

Breakthrough Hope for HCM Patients: Cytokinetics Unveils Promising Aficamten Data at European Cardiology Congress
Cytokinetics Unveils Groundbreaking MAPLE-HCM Results for Aficamten at ESC Congress

Cytokinetics Unveils Groundbreaking MAPLE-HCM Results for Aficamten at ESC Congress
Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report

Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report
Novartis said to have backed away from a deal for Cytokinetics

Novartis said to have backed away from a deal for Cytokinetics
Load more..